Karrer K, Denck H, Karnicka-Mlodkowska H, Drings P, Orel J, Salzer G M, Thermann M, Lattuneddu A, Sun Y, Hata E
Institute for Epidemiology of Neoplasms of the University of Vienna, Austria.
Med Oncol Tumor Pharmacother. 1989;6(2):143-9. doi: 10.1007/BF02985237.
For the optimisation of the therapy for small cell bronchial carcinomas (SCLC), surgery is used to eliminate the primary tumor and its regional lymph nodes and chemo- and radiotherapy for the general treatment of micrometastasis. After patho-histological examination of the operation specimen, randomization for two arms is performed for a standard chemotherapy (CAV) or a sequential chemotherapy using three different drug combinations. Thereafter all disease-free patients receive prophylactic cranial irradiation (PCI). Preliminary evaluations in December 1987, of 112 patients from 19 cooperating departments show that the survival rate projected for 2 yr of 43 patients at stage pT1-3 N0 M0 is 76%, of 43 patients at stage pT1-3 N1 M0 it is 63% and of 26 patients at stage pT1-3 N2 M0 it is 38%.
为优化小细胞支气管癌（SCLC）的治疗方案，采用手术切除原发性肿瘤及其区域淋巴结，并采用化疗和放疗来全面治疗微转移。对手术标本进行病理组织学检查后，将患者随机分为两组，分别接受标准化疗（CAV）或使用三种不同药物组合的序贯化疗。此后，所有无病患者均接受预防性颅脑照射（PCI）。1987年12月对来自19个合作科室的112例患者进行的初步评估显示，pT1-3 N0 M0期43例患者的2年预计生存率为76%，pT1-3 N1 M0期43例患者为63%，pT1-3 N2 M0期26例患者为38%。
